IP Library Granted Patent US 10,933,167
Granted Patent B2
US 10,933,167 · App. 16/059,935 · Granted Mar 2, 2021

Injectable scaffold composition and related methods

Inventors: Patrick Ginty (Nottingham, GB); Robin Andrew Quirk (Nottingham, GB); Kevin Morris Shakesheff (Nottingham, GB)
Assignee: LOCATE THERAPEUTICS LIMITED
A61L27/502A61L27/26A61L27/38A61L27/50A61L27/54A61L27/58A61L27/60A61L2300/602A61L2400/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,933,167
App. No.
16/059,935
Granted
Mar 2, 2021
Kind
B2
Abstract

A composition comprising polymer particles and a carrier, wherein the polymer particles are a mixture of at least a first polymer and a second polymer, wherein the first polymer is at least partially soluble or dispersible in the carrier, and wherein the polymer particles are arranged such that they can join together to form a scaffold of polymer particles, and wherein the composition is administrable to a human or non-human animal.

Claims (15)

1. A method of producing a scaffold in vivo in a human or non-human animal, comprising:

(a) forming a scaffold by combining polymer particles capable of cross-linking with an aqueous carrier to form a composition that is administered in vivo in a human or non-human animal prior to the hardening of the scaffold, wherein the polymer particles comprise a first polymer and a second polymer, wherein the first polymer is a plasticizer having a molecular weight of 800 Da or less and is soluble or dispersible in the carrier, such that 1 wt % or more of the first polymer leach into the carrier within 20 hours at 25° C. immediately after combining the first and second polymers with the carrier,

wherein the second polymer is an amorphous or semi-crystalline polymer,

wherein the amount of the first polymer present in the polymer particles is from 1 to 20% by weight and the ratio of polymer to carrier is from 4:1 to 1:4,

wherein the polymer particles have a glass transition temperature lower than the glass transition temperature of the second polymer on its own,

wherein the polymer particles cross-link in vivo by one or more of fusion, adhesion, cohesion, and entanglement to form a scaffold of polymer particles; and

wherein the scaffold is formed in vivo by removal of the first polymer from the scaffold of polymer particles by leaching, which results in a hardened scaffold structure.

2. The method of claim 1 , wherein the polymer particles have a glass transition temperature of 45° C. or less.

3. The method of claim 2 , wherein the polymer particles have a glass transition temperature of 37° C. or less and wherein the glass transition temperature of the polymer particles is lower than the glass transition temperature of the second polymer particle on its own.

4. The method of claim 1 , wherein the plasticizer having a molecular weight of 800 Da or less is selected from the group consisting of: polyethylene glycol (PEG), poly(propylene adipate) (PPA), polyt(butylene adipate) (PBA), poly lactic acid (PLA), polyglycolic acids (PGA), poly(D,Lvlactide-co-glycolide)(PLGA), poly propylene glycol, poly capralactone, polyethylene glycol polypropylene block co-polymers.

5. The method of claim 4 , wherein the plasticizer having a molecular weight of 800 Da or less is PEG.

6. The method of claim 5 , wherein the plasticiser is PEG having a molecular weight of 400 Da or less.

7. The method of claim 1 , wherein the amount of the first polymer present in the polymer particles is from 3% to 10% by weight.

8. The method of claim 1 , wherein the second polymer is selected from the group comprising poly lactic acid (PLA), polyglycolic acids, poly(D,L-Iactide-co-glycolide)(PLGA), poly D,LIactic acid (PDLLA), poly-Iactide poly-glycolide copolymers and combinations thereof.

9. The method of claim 7 , wherein the first polymer is PEG and the second polymer is PLGA.

Assignments (1)
CHANGE OF NAME Recorded Aug 9, 2018
From: REGENTEC LTD.
To: LOCATE THERAPEUTICS LIMITED
Reel/Frame 046758/0545 →
Priority Claims (1)
GB 0701896.3 · Feb 1, 2007 · national
Continuity (2)
Continuation 12525195
Related Publication 20180361029A1 · Dec 20, 2018